Arrowhead Pharmaceuticals

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Retrieved on: 
Mercoledì, Maggio 15, 2024
ACT, Plasma, Toxicity, AAN, Investment, Neurodegenerative disease, IND, Ageing, GBA1, Drug development, ADAS, Excitotoxicity, Inflammation, Therapy, ALS, Neurotrophic factors, American Academy, Survival, DSM-IV codes, Conference, Research and development, SHAPE, Administration, Cognition, Food and Drug Administration, Food, Arrowhead Pharmaceuticals, Doctor of Philosophy, Disease, Pathology, Poster, ERP, Central nervous system, Patient, Lewy body, Investigational New Drug, HGF, Treatment, Drug discovery, Biomarker, Frontiers, Dementia, GST, Annual general meeting, Pharmaceutical industry

BOTHELL, Wash., May 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2024, and provided recent pipeline and business updates.

Key Points: 
  • Athira expects to report topline data from LIFT-AD in the second half of 2024.
  • Athira expects to initiate a first-in-human study of ATH-1105 in the second quarter of 2024.
  • R&D expenses were $21.2 million for the quarter ended March 31, 2024, compared to $21.3 million for the quarter ended March 31, 2023.
  • G&A expenses were $6.5 million for the quarter ended March 31, 2024, compared to $8.5 million for the quarter ended March 31, 2023.

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Retrieved on: 
Venerdì, Maggio 17, 2024
Professional Services, Health, Infectious Diseases, Finance, Pharmaceutical, Biotechnology, Moderna, HBsAg, Partnership, Arrowhead, Arbutus Biopharma, Special, Patent, Johnson & Johnson, GSK, Vaccine, Congress, COVID, RNA, District court, Therapy, Probability, Hepatitis, Retirement, Letter, Arrowhead Pharmaceuticals, Sale, HBV, BioNTech, GSK plc, ATM, PD-L1, Hepatitis B, LNP, Clinical trial, Interim, Roivant Sciences, Patient, RNA interference, EASL, Moderna COVID-19 vaccine, Combo, Janssen Pharmaceuticals, Pharmaceutical industry

Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the second largest shareholder of Arbutus Biopharma Corp. (NASDAQ: ABUS) (“Arbutus” or the “Company”) with an ownership interest of approximately 6.8% of the Company’s outstanding shares, today published an open letter to shareholders outlining its views of the best paths forward to maximize value.

Key Points: 
  • Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the second largest shareholder of Arbutus Biopharma Corp. (NASDAQ: ABUS) (“Arbutus” or the “Company”) with an ownership interest of approximately 6.8% of the Company’s outstanding shares, today published an open letter to shareholders outlining its views of the best paths forward to maximize value.
  • Whitefort is a long-term investor in Arbutus, having continuously held shares since October 2022.
  • We also want to ensure that the Board of Directors (the “Board”) and our fellow shareholders understand the urgency of these issues.
  • However, we believe that Arbutus should firmly commit to cease any further share issuances for the foreseeable future, including under the ATM program.

JNJ-73763989 (JNJ-6379) for Chronic Hepatitis B in 6MM: Market Size, Forecasts, and Emerging Insight 2019-2023 & 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Maggio 17, 2024
Infectious Diseases, Pharmaceutical, Health, Clinical Trials, CccDNA, Patient, DNA, SWOT, Clinical trial, Arrowhead Pharmaceuticals, HBV, Janssen Pharmaceuticals, DDI, Research, Hepatitis, RNA interference, EU4, Vaccine

"JNJ-73763989 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about JNJ-73763989 for chronic hepatitis B in the six major markets.

Key Points: 
  • "JNJ-73763989 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about JNJ-73763989 for chronic hepatitis B in the six major markets.
  • Other emerging products for chronic hepatitis B are expected to give tough market competition to JNJ-73763989 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What are the other emerging products available and how are these giving competition to JNJ-73763989 for chronic hepatitis B?
  • Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

Turnstone Biologics Appoints William Waddill to its Board of Directors

Retrieved on: 
Martedì, Aprile 16, 2024
University, CFO, LLP, Champaign–Urbana metropolitan area, Certification, Arrowhead Pharmaceuticals, TILS, PwC, Biotechnology Innovation Organization, BIO, Selection, TIL, SVP, Senior, Patient, OncoMed, Therapy, Biotechnology, SAN, Pharmaceutical industry

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.

Key Points: 
  • SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.
  • The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors.
  • “I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone,” said Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer.
  • “Will is a highly accomplished biotechnology executive and Board member, and his impressive track record and deep operational and financial acumen make him a valuable addition to our Board.

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Retrieved on: 
Lunedì, Aprile 15, 2024
Doctor of Philosophy, Denosumab, University, Arrowhead Pharmaceuticals, Eli Lilly, Compensated emancipation, Internal medicine, International development, Employment, HGF, Lundbeck Seattle Biopharmaceuticals, Athira Pharma, Therapy, Senior, Hypophosphatemia, Patient, ALS, DSM-IV codes, Ultragenyx, Drug development, Burosumab, Growth, Pharmaceutical industry

BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer.

Key Points: 
  • BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer.
  • “We are pleased to welcome Javier to the team and are confident his insights and guidance will be instrumental as we advance the Company’s next phase of growth,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • Before that, Dr. San Martin served as Senior Vice President of Clinical Development at Alder Biopharmaceuticals, where he managed medical, regulatory, and clinical operations.
  • In addition, Athira today announced, as required by The Nasdaq Stock Market Rules, an equity inducement award to Dr. San Martin, the Company’s new Chief Medical Officer.

RegCell Appoints Leading T-Cell Therapy Expert Steven B. Kanner, Ph.D., to Board of Directors

Retrieved on: 
Mercoledì, Aprile 3, 2024
Cell, Rachel Haurwitz, Drug discovery, Genetics, Inflammation, Patient, Arrowhead Pharmaceuticals, Research, Bristol Myers Squibb, University, Publication, Reindeer, Microbiology, Regulatory T cell, RNA interference, Immune system, Therapy, Bangladesh Technical Education Board, Book, Astex Pharmaceuticals, Vaccine

"We are honored to have Steve Kanner join our Board of Directors," remarked Professor Shimon Sakaguchi, co-founder of RegCell.

Key Points: 
  • "We are honored to have Steve Kanner join our Board of Directors," remarked Professor Shimon Sakaguchi, co-founder of RegCell.
  • "Dr. Kanner's profound understanding of immunology comes at a pivotal juncture for RegCell as we advance our clinical development and expand our Precision Epigenetic Reprogramming Platform.
  • Backed by leading institutional and corporate investors hailing from Japan, RegCell emerges as the next-generation global life science enterprise at the forefront of regulatory T-cell therapies.
  • Central to RegCell's innovation is its 'Precision Epigenetic Reprogramming' platform, which entails the epigenetic reprogramming of CD4+ T-cells into regulatory T-cells.

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results

Retrieved on: 
Lunedì, Gennaio 22, 2024
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, PIN, Arrowhead Pharmaceuticals, Webcast

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m.
  • ET to discuss its financial results for the fiscal first quarter ended December 31, 2023.
  • Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm .
  • A replay of the webcast will be available approximately two hours after the conclusion of the call.

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease

Retrieved on: 
Giovedì, Dicembre 21, 2023
Health, Medical Devices, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Committee, RNA, Liver, RNA interference, System, CFB, Kidney, Kidney disease, Glomerulonephritis, Translational medicine, Arrowhead Pharmaceuticals, Arrowhead, MBA, Clinical trial, Pharmacokinetics, Complement factor B, Ethics committee, Discovery, Safety, Patient, Pharmaceutical industry

Additionally, ARO-CFB may have clinical applications in non-renal diseases involving complement activation.

Key Points: 
  • Additionally, ARO-CFB may have clinical applications in non-renal diseases involving complement activation.
  • ARO-CFB is designed to reduce hepatic expression of complement factor B (CFB), which plays an important regulatory role in amplifying complement alternative pathway activation and has been identified as a promising therapeutic target.
  • James Hamilton, M.D., MBA, Chief of Discovery and Translational Medicine at Arrowhead, said: “IgAN is the most common glomerular disease worldwide, accounting for up to 40% of all cases of glomerulonephritis.
  • Pending clearance, Arrowhead intends to proceed with AROCFB-1001, a Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-CFB in up to 66 healthy volunteers and patients with complement mediated kidney disease.

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Retrieved on: 
Martedì, Novembre 28, 2023
Biotechnology, Medical Devices, Health, Pharmaceutical, Clinical Trials, Life expectancy, Safety, Cataract, RNA interference, Exercise, Arrowhead, Clinical trial, DMPK, DM1, Wheelchair, Pharmacokinetics, Muscle weakness, Messenger, Therapy, Ethics committee, MBA, Committee, Wasting, Myotonia, Arrowhead Pharmaceuticals, Patient, Facial muscles, Discovery, Translational medicine, RNA, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy.
  • ARO-DM1 is designed to reduce expression of the dystrophia myotonica protein kinase (DMPK) gene.
  • Treatments have focused on symptomatic management, including physical therapy, exercise, ankle-foot orthoses, wheelchairs, and other assistive devices.
  • Pending clearance, Arrowhead intends to proceed with ARODM1-1001, a Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-DM1 in up to 48 subjects with DM1.

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results

Retrieved on: 
Giovedì, Novembre 16, 2023
Genetics, Pharmaceutical, Health, Webcast, Arrowhead Pharmaceuticals, PIN

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 29, 2023, at 4:30 p.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 29, 2023, at 4:30 p.m.
  • ET to discuss its financial results for the fiscal year ended September 30, 2023.
  • Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm .
  • A replay of the webcast will be available approximately two hours after the conclusion of the call.